Table 1.
Main characteristics of the 99 participants
| N(%) | |
|---|---|
| Asia and Oceanic ocean | |
| Australia | 1 (1.0%) |
| China | 1 (1.0%) |
| Israel | 1 (1.0%) |
| Japan | 8 (8.1%) |
| Singapore | 1 (1.0%) |
| Europe | |
| Belgium | 1(1.0%) |
| Denmark | 2 (2.0%) |
| France | 16 (16.2%) |
| Italy | 5 (5.1%) |
| Germany | 5 (5.1%) |
| Greece | 3 (3.0%) |
| Spain | 1 (1.0%) |
| Sweden | 1 (1.0%) |
| Switzerland | 5 (5.1%) |
| UK | 4 (4.0%) |
| North America | |
| Canada | 2 (2.0%) |
| USA | 42 (42.4%) |
| Status | |
| Statistician | 22 (22.2%) |
| Physician | 73 (73.8%) |
| Other | 4 (4.0%) |
| Employer | |
| Academic | 80 (80.8%) |
| Industry | 9 (9.1%) |
| Other | 10 (10.1%) |
| Experience in the conduct of phase I trials | |
| <5 years | 9 (9.1%) |
| 5–10 years | 34 (34.4%) |
| 10–15 years | 23 (23.2%) |
| >15 years | 32 (32.3%) |
| Not specified | 1 (1.0%) |